Which condition requires caution with aminoglycosides due to possible neuromuscular weakness?

Which condition requires caution with aminoglycosides due to possible neuromuscular weakness?

• A. Myasthenia Gravis
• B. Hypertension
• C. Hyperlipidemia
• D. Diabetes

Answer: (A)

Aminoglycosides can impair neuromuscular transmission by reducing acetylcholine release at the neuromuscular junction and potentiating neuromuscular blockade. In myasthenia gravis, there are fewer functional acetylcholine receptors at the motor end plate, so the safety margin for muscle contraction is already reduced. Adding an aminoglycoside can tip the balance toward marked weakness and even respiratory failure. This is why caution is needed in this condition. The other listed conditions do not inherently create the same risk for neuromuscular weakness with aminoglycosides.

Aminoglycosides can impair neuromuscular transmission by reducing acetylcholine release at the neuromuscular junction and potentiating neuromuscular blockade. In myasthenia gravis, there are fewer functional acetylcholine receptors at the motor end plate, so the safety margin for muscle contraction is already reduced. Adding an aminoglycoside can tip the balance toward marked weakness and even respiratory failure. This is why caution is needed in this condition. The other listed conditions do not inherently create the same risk for neuromuscular weakness with aminoglycosides.